ClinicalTrials.gg
CompletedNCT00644605Updated Feb 1, 2021

A Study to Assess the Efficacy and Safety of 20, 40, and 80mg of Sildenafil Three Times a Day in the Treatment of Pulmonary Arterial Hypertension

A Phase 3 interventional study of sildenafil and sildenafil in Hypertension, Pulmonary, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 68 sites in 23 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-01.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
275
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 51 studies testing sildenafil in Hypertension, Pulmonary — 1 open to participants now, 1 under way, none of them phase 3. sildenafil · Hypertension, Pulmonary.

Planned enrollment
2nd of 50
275 · median 30
Started
2002
with 1 other
Phase 3
15 of 51
none open now
Registered
15th of 51
by date
Lead sponsor
7 of 51
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 51 studies testing sildenafil in Hypertension, Pulmonary, this one is the 2nd largest by planned enrollment of the 50 interventional ones that give a count, is one of 2 that started in 2002, is one of 15 in phase 3, and was the 15th registered.

Hypertension, Pulmonary

1,092 studies on the registry are indexed under Hypertension, Pulmonary; 244 are open to participants now.

Browse Hypertension, Pulmonary studies →

Open to participants now

1 of the 51 studies testing sildenafil in Hypertension, Pulmonary is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About sildenafil

sildenafil: first FDA approval 1998 (VIAGRA), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 164 Hypertension, Pulmonary studies recruiting now, 99 (60%) set no upper age limit and 26 (16%) stop at 75 or younger; 39 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies testing sildenafil in Hypertension, Pulmonary, or all of them as a file.
02

Study summary

To evaluate the effect of three doses of oral sildenafil (20, 40 and 80 mg three times a day [TID]) on exercise capacity, as measured by the 6-Minute Walk test, as well as the safety and tolerability, after 12 weeks of treatment in subjects with pulmonary arterial hypertension who are aged 18 years and over. To investigate the plasma concentration-effect relationship and to determine the population pharmacokinetic (PK) parameters.

03

Conditions studied

  • Hypertension, Pulmonary
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Included patients had primary pulmonary arterial hypertension, pulmonary hypertension secondary to connective tissue disease, or pulmonary hypertension with surgical repair at least 5 years previously; a mean pulmonary artery pressure greater than or equal to 25 mmHg and a pulmonary artery wedge pressure of less than or equal to 15 mmHg at rest, via right heart catheterisation within 21 days prior to randomisation; and a baseline 6-Minute Walk test distance of 100 m to 450 m.

Exclusion criteria

Exclusion Criteria:

Subjects with congenital heart disease, pulmonary hypertension due to thromboembolism, , chronic obstructive airway disease, congestive heart failure or schistosomiasis; subjects with significant (ie > 2+) valvular disease other than tricuspid regurgitation or pulmonary regurgitation; and acutely decompensated heart failure within the previous 30 days; subjects with pulmonary hypertension secondary to any other etiology other than those specified in the inclusion criteria.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
275 participants (estimated)

Study arms

  • Active comparator
    Arm 1

    Drug: sildenafil

  • Active comparator
    Arm 2

    Drug: sildenafil

  • Active comparator
    Arm 3

    Drug: sildenafil

  • Placebo comparator
    Arm 4

    Drug: placebo

Interventions

  • sildenafil 40 mg by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks

  • sildenafil 80 mg by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks; initially, patients received 40mg TID for one week and were then up-titrated to 80mg TID

  • Drugplacebo

    placebo by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks

  • sildenafil 20 mg by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks

06

What researchers measure

Primary outcomes

  1. Change from baseline in exercise capacity, as measured by distance walked in six minutes (6-Minute Walk test).

    Time frame: Week 12

Secondary outcomes

  1. Change from baseline in mean pulmonary arterial pressure

    Time frame: Week 12

  2. Time from randomisation to the first occurrence of clinical worsening (death or lung transplantation or hospitalisation due to pulmonary hypertension or initiation of prostacyclin therapy or initiation of bosentan therapy)

    Time frame: Week 0 to 12

  3. Change from baseline in the BORG dyspnoea score

    Time frame: Week 12

  4. Change from baseline in pulmonary hypertension criteria for functional capacity and therapeutic class

    Time frame: Week 12

  5. Change from baseline in the 8 dimensions of SF-36 (Physical functioning, Role functioning, Bodily pain, General health, Vitality, Social functioning, Mental health and Reported health transition)

    Time frame: Week 4 and Week 12

  6. Change from baseline at Weeks 4 and 12 in the 5 dimensions of ED5Q (Mobility, Self care, Usual Activities, Pain/Discomfort and Anxiety/Depression)

    Time frame: Week 4 and Week 12

  7. Patient overall preference assessment

    Time frame: Week 12

  8. Change in Chronic Use of Background Therapy for Pulmonary Arterial Hypertension

    Time frame: throughout the study

  9. Change from baseline in hemodynamic parameters

    Time frame: Week 12

07

Study locations

68 sites
  • Pfizer Investigational Site
    Birmingham, Alabama 35233, United States
  • Pfizer Investigational Site
    Birmingham, Alabama 35294-0006, United States
  • Pfizer Investigational Site
    Birmingham, Alabama 35294, United States
  • Pfizer Investigational Site
    La Jolla, California 92037, United States
  • Pfizer Investigational Site
    La Jolla, California 92093, United States
  • Pfizer Investigational Site
    Los Angeles, California 90024, United States
  • Pfizer Investigational Site
    Los Angeles, California 90033, United States
  • Pfizer Investigational Site
    Los Angeles, California 90095, United States
  • Pfizer Investigational Site
    San Diego, California 92037, United States
  • Pfizer Investigational Site
    Torrance, California 90502, United States
  • Pfizer Investigational Site
    Torrance, California 90509, United States
  • Pfizer Investigational Site
    Aurora, Colorado 80010, United States
  • Pfizer Investigational Site
    Denver, Colorado 80262, United States
  • Pfizer Investigational Site
    Chicago, Illinois 60612, United States
  • Pfizer Investigational Site
    Shreveport, Louisiana 71103, United States
  • Pfizer Investigational Site
    Baltimore, Maryland 21205, United States
  • Pfizer Investigational Site
    Boston, Massachusetts 02111, United States
  • Pfizer Investigational Site
    Ann Arbor, Michigan 48109, United States
  • Pfizer Investigational Site
    Rochester, Minnesota 55905, United States
  • Pfizer Investigational Site
    New York, New York 10032, United States
  • Pfizer Investigational Site
    Durham, North Carolina 27710, United States
  • Pfizer Investigational Site
    Nashville, Tennessee 37232, United States
  • Pfizer Investigational Site
    Houston, Texas 77030, United States
  • Pfizer Investigational Site
    Milwaukee, Wisconsin 53215, United States
  • Pfizer Investigational Site
    Darlinghurst, New South Wales 2010, Australia
  • Pfizer Investigational Site
    Melbourne, Victoria 3004, Australia
  • Pfizer Investigational Site
    Bruxelles, 1070, Belgium
  • Pfizer Investigational Site
    Leuven, 3000, Belgium
  • Pfizer Investigational Site
    Sao Paulo, SP 05403-900, Brazil
  • Pfizer Investigational Site
    Prague 4, 140 00, Czechia
  • Pfizer Investigational Site
    Prague 4, 140 21, Czechia
  • Pfizer Investigational Site
    Kobenhavn, 2100, Denmark
  • Pfizer Investigational Site
    Clamart, 92141, France
  • Pfizer Investigational Site
    Berlin, 13353, Germany
  • Pfizer Investigational Site
    Giessen, 35385, Germany
  • Pfizer Investigational Site
    Giessen, 35392, Germany
  • Pfizer Investigational Site
    Hannover, 30625, Germany
  • Pfizer Investigational Site
    Leipzig, 04103, Germany
  • Pfizer Investigational Site
    Shatin N T, Hong Kong
  • Pfizer Investigational Site
    Budapest, Pest 1529, Hungary
  • Pfizer Investigational Site
    Zalaegerszeg, Zala 8900, Hungary
  • Pfizer Investigational Site
    Petach Tikva, 49100, Israel
  • Pfizer Investigational Site
    Tel Hashomer, 52621, Israel
  • Pfizer Investigational Site
    Bologna, 40138, Italy
  • Pfizer Investigational Site
    Pisa, 56124, Italy
  • Pfizer Investigational Site
    Pisa, 56126, Italy
  • Pfizer Investigational Site
    Suwon, 442-721, Korea, Republic of
  • Pfizer Investigational Site
    Kuala Lumpur, 59100, Malaysia
  • Pfizer Investigational Site
    Tlalpan, Mexico
  • Pfizer Investigational Site
    Amsterdam, 1081 HV, Netherlands
  • Pfizer Investigational Site
    Oslo, NO-0027, Norway
  • Pfizer Investigational Site
    Katowice, 40-057, Poland
  • Pfizer Investigational Site
    Warszawa, 01-138, Poland
  • Pfizer Investigational Site
    Warszawa, 03-709, Poland
  • Pfizer Investigational Site
    Zabrze, 41-800, Poland
  • Pfizer Investigational Site
    Singapore, 168752, Singapore
  • Pfizer Investigational Site
    Cape Town, 7700, South Africa
  • Pfizer Investigational Site
    Johannesburg, 2193, South Africa
  • Pfizer Investigational Site
    Parow, South Africa
  • Pfizer Investigational Site
    Barcelona, 08035, Spain
  • Pfizer Investigational Site
    Barcelona, 08036, Spain
  • Pfizer Investigational Site
    Madrid, 28041, Spain
  • Pfizer Investigational Site
    Goteborg, 413 45, Sweden
  • Pfizer Investigational Site
    Molndal, 431 80, Sweden
  • Pfizer Investigational Site
    Papworth Everard, Cambridgeshire CB3 8RE, United Kingdom
  • Pfizer Investigational Site
    Sheffield, South Yorkshire S10 2JF, United Kingdom
  • Pfizer Investigational Site
    Glasgow, G11 6NT, United Kingdom
  • Pfizer Investigational Site
    HIGH Heaton, Newcastle-upon-tyne, NE7 7DW, United Kingdom
08

References and documents

Publications

  • Wirostko BM, Tressler C, Hwang LJ, Burgess G, Laties AM. Ocular safety of sildenafil citrate when administered chronically for pulmonary arterial hypertension: results from phase III, randomised, double masked, placebo controlled trial and open label extension. BMJ. 2012 Feb 21;344:e554. doi: 10.1136/bmj.e554. PubMed 22354598 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2002 and a completion of Nov 2003. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2008
First posted
Mar 27, 2008
Start
Oct 2002
CompletionActual
Nov 2003
Last update
Feb 1, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 1, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00644605
Responsible party
Sponsor
First posted
Mar 27, 2008
Start date
Oct 2002
Completion
Nov 2003
Last update
Feb 1, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sildenafil

Start the discussion